Chardan raised the firm's price target on Alumis to $40 from $38 and keeps a Buy rating on the shares, reflecting updated pricing assumptions for envudeucitinib, modest changes in psoriasis penetration, and updated financials after the company reported Q1 results and provided a business update.
